In their annual report, PSI highlighted several key sponsor-specific takeaways:

• In an industry characterized by unpredictability, PSI’s key differentiator is on-time project delivery. FPI and LPI were achieved as planned in 95% and 97% of studies – an improvement on 2024 metrics. Sponsors could maintain study momentum, manage budgets effectively, and bring new treatments to patients quicker
• Revenue growth of 15%, supported by a strong backlog and a D&B rating of 1 (the highest performing financial status) indicates sponsors continue to have confidence in PSI’s longevity and commitment to running trials with minimal risk of disruption
• Beyond data demonstrating continued industry leadership in oncology, IBD and GI, radiopharmaceuticals, neuroscience, and infectious disease, growth in other therapeutic areas means sponsors can rely on PSI’s expertise no matter the therapeutic area, reducing risk and improving predictability in complex, pivotal trials
• Operational highlights included the formal launch of the Specialized Study Support Services team (to absorb the operational burden that sites can face, so that enrollment, data quality, and timelines don’t suffer), and a 38% increase in global site activation from last year
• The launch of SYNETIC, an agentic AI platform bringing years of global site performance data to generate accurate site lists, faster startup, and more predictable enrollment for sponsors

PSI’s strategic promises for 2026 only echo the above. The desire to improve upon predictability in an industry known for its volatility. Increasing and expanding operational presence in top-enrolling regions and continuing to grow global teams are two pledges that are sure to strengthen the metrics for 2026, and help sponsors achieve their goals.